Plecanitide

After market close on January 19, Synergy Pharmaceuticals Inc (NASDAQ: SGYP) reported that it had achieved FDA approval for its lead drug, plecanatide, in constipation-predominant irritable bowel syndrome (IBS-C). Rodman & Renshaw’s Raghuram Selvaraju reiterated a Buy rating on the...